Maxime Dely: What If Whole Blood Became the Standard Again in Massive Transfusion?
Maxime Dely, Therapeutic Solutions Sales Consultant at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
“What if whole blood became the standard again in massive transfusion?
In the management of massive hemorrhage, current protocols are well established: alternating red blood cell concentrates, plasma, and platelets – a structured sequence designed to approximate whole blood.
But an important question is increasingly being raised:
Why not use leukoreduced whole blood directly?
The advantages are clear:
- A product that is inherently complete and balanced
- Simplified logistics (single storage condition and unified shelf-life considerations)
- More efficient inventory management
From a scientific standpoint, several recent studies indicate that whole blood offers efficacy comparable to component therapy, particularly regarding early survival and correction of coagulopathy.
Beyond clinical outcomes, this also prompts broader reflection on our organizational models.
And you – have your institutions already begun exploring this shift?”
Find more posts featuring Maxime Dely on Hemostasis Today.
-
Sep 24, 2026, 18:43Hugh Nguyen: Honored to Accept the Friend of Singapore Red Cross Award
-
Sep 24, 2026, 18:42Titilope Fasipe: Proud to Support American Society of Hematology’s SCD Initiative
-
Sep 24, 2026, 18:34Ifeanyichukwu Ifechidere: Why Coagulation Samples Can Be “Too Valuable to Throw Away”?
-
Sep 24, 2026, 18:33Aswin K. Mohan: When a Superpower Hears the Call for Blood
-
Sep 24, 2026, 18:31Mercy Lung’aho: Anemia Is Not Only An Iron Problem
-
Sep 24, 2026, 18:29Nick Hanson: Before a Dementia Diagnosis Check Vitamin B12
-
Sep 24, 2026, 18:28Rachel McBryan: Nearly One in Five Older Canadians Has Low Vitamin B12
-
Sep 24, 2026, 18:27Kemal Karaagac: Early DOAC Initiation After Acute Ischaemic Stroke in Atrial Fibrillation
-
Sep 24, 2026, 18:26Mohammed A. AlOmar: What Characterizes Young Stroke in the UAE?